Elevation Point Wealth Partners LLC raised its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK – Free Report) by 376.3% in the first quarter, Holdings Channel reports. The firm owned 141,882 shares of the company’s stock after buying an additional 112,092 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Takeda Pharmaceutical were worth $2,628,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in TAK. Private Trust Co. NA grew its stake in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd lifted its stake in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Takeda Pharmaceutical Trading Down 0.2%
Shares of TAK stock opened at $16.73 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a market cap of $53.26 billion, a PE ratio of 42.91 and a beta of -0.07. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $16.09 and its two-hundred day moving average is $16.86.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on TAK shares. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Sunday, June 28th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Finally, Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold”.
Check Out Our Latest Research Report on Takeda Pharmaceutical
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Featured Stories
- Five stocks we like better than Takeda Pharmaceutical
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
